Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

ELTX

+ Watchlist+ Portfolio

Elicio Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.43
52-Week Range
$1.25 – $16.00
Market Cap
$45.01M
P/E (TTM)
—
EPS (TTM)
-1.81
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.39
PEG Ratio
—
Return on Equity
-315.32%
Return on Assets
-70.58%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
3.43
Debt/Equity
0.74
Total Debt
$13.99M
Free Cash Flow
$-21.18M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$28.10M

Market Snapshot

About

Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company's proprietary Amphiphile (AMP) platform technology is designed to direct immune responses to lymph nodes, where T cells are activated. Elicio's lead programs focus on cancer vaccines and immunomodulatory therapies that aim to generate robust and durable anti-tumor immune responses. The company is conducting clinical trials in multiple cancer types, including pancreatic cancer and other solid tumors with significant unmet medical needs.